+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Beta-propiolactone plus ultraviolet irradiated plasma. A clinical evaluation for hepatitis, toxicity and allergy

Beta-propiolactone plus ultraviolet irradiated plasma. A clinical evaluation for hepatitis, toxicity and allergy

Proceedings Congress Int Society Blood Transfus 9: 644-647

The treatment of plasma with beta-propiolactone (BPL) has been studied clinically for a 10 year period: A 4 year study (1951-1956), during which time BPL was used alone as the sterilizing agent, and the present 6 year report (1956-61), during which time the pooled plasma was treated by the combined procedure of beta-protiolactone plus ultraviolet irradiation. In this 10 year period, 995 plasma recipients received a total of 2563 transfusions without evidence of clinical hepatitis, toxicity or allergic reactions proved to be attributable to the treated plasma.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 024232466

Download citation: RISBibTeXText

Related references

Beta-Propiolactone Plus Ultraviolet Irradiated Plasma. a Clinical Evaluation for Hepatitis, Toxicity and Allergy. Bibliotheca Haematologica 19: 644-647, 1964

Clinical evaluation of the hepatitis safety of a beta-propiolactone/ultraviolet treated factor IX concentrate (PPSB). Thrombosis Research 28(1): 75-83, 1982

Inactivation of hepatitis A virus added to pooled human plasma by beta-propiolactone treatment and ultraviolet irradiation. European Journal of Clinical Microbiology 2(4): 355-357, 1983

Human Plasma Treated with Ultraviolet and Propiolactone. Six-Year Clinical Evaluation. JAMA 187: 722-726, 1964

Propiolactone plus ultraviolet-treated plasma without hepatitis. Arch Surg 88(4): 721-724, 1964

Serum hepatitis and the clinical evaluation of blood components sterilized with beta-propiolactone. Bibliotheca Haematologica 13: 504-509, 1962

Inactivation of hepatitis B and non-A, non-B viruses by combined use of Tween 80, beta-propiolactone, and ultraviolet irradiation. Thrombosis and Haemostasis 50(2): 534-536, 1983

Effect of combined beta-propiolactone/ultraviolet irradiation treatment on hepatitis B virus. Lancet 2(8200): 917, 1980

Evaluation of thrombogenicity of beta-propiolactone/ultraviolet (beta-PL/UV) treated PPSB in chimpanzees. Thrombosis Research 30(3): 235-244, 1983

The safety of beta-propiolactone as a biologic sterilizing agent. Clinical evaluation with human plasma and homotransplants. Angiology 12: 80-83, 1961

Inactivation of the Hutchinson strain of non-A, non-B hepatitis virus by combined use of beta-propiolactone and ultraviolet irradiation. Journal of Medical Virology 16(2): 119-125, 1985

Effect of combined treatment of serum containing hepatitis B virus with beta-propiolactone and ultraviolet irradiation. Vox Sanguinis 41(3): 134-138, 1981

Homologous serum hepatitis after transfusions of blood and ultraviolet-irradiated plasma; clinical observations. Texas State Journal of Medicine 47(12): 831-835, 1951

Inactivation of hepatitis viruses and HIV in plasma and plasma derivatives by treatment with beta-propiolactone/UV irradiation. Current Studies in Hematology and Blood Transfusion 1989(56): 122-127, 1989

Inactivation of hepatitis viruses and hiv in plasma and plasma derivatives by combined treatment with beta propiolactone uv irradiation. Thrombosis and Haemostasis 58(1): 370, 1987